Anti-HIV Effects of Chloroquine
- 1 March 2004
- journal article
- basic science
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 35 (3) , 223-232
- https://doi.org/10.1097/00126334-200403010-00002
Abstract
Objective We tested the effects of chloroquine (CQ) on glycosylation of HIV particles and in combination with protease inhibitors (PIs) on HIV replication and on P-glycoprotein (P-gp)/multidrug resistance protein-1 (MRP1). Design CD4+ cell lines were infected with laboratory strains and peripheral blood mononuclear cells were infected with primary isolates for evaluation of the anti-HIV effects. Peripheral blood lymphocytes were evaluated for of P-gp and MRP1 functions. Methods HIV replication was assessed by enzyme-linked immunosorbent assay. HIV glycosylation was measured by metabolic labeling of viral particles with [3H] glucosamine. Synergism was tested using isobolograms. P-gp and MRP1 functions were assayed using rhodamine 123 (Rh123) and carboxyfluorescein (CF) efflux assays, respectively. Results CQ alone inhibited HIV replication and glycosylation in a dose-dependent manner. In combination with indinavir (IDV), ritonavir, or saquinavir (SQV), CQ had a synergistic effect at concentrations found in plasma of subjects receiving malaria prophylaxis. CQ decreased the 50% effective concentration of IDV in primary isolates from Africa and restored the response to IDV or SQV in 3 PI-resistant isolates. CQ increased the block of Rh123 and CF efflux activity exerted by PIs. Conclusion The inhibitory effects of CQ on HIV glycosylation are associated with synergistic effects in combination with PIs. The CQ/PI combination exerts combined inhibitory effects on P-gp and MRP1 function.Keywords
This publication has 37 references indexed in Scilit:
- Human CD38 interferes with HIV‐1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.The FASEB Journal, 2003
- Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug‐Naive Patients Treated with Protease Inhibitor–Based TherapyThe Journal of Infectious Diseases, 2001
- ABC of AIDS: Antiretroviral drugsBMJ, 2001
- Chloroquine Exerts an Additive in Vitro Anti-HIV Type 1 Effect When Associated with Didanosine and HydroxyureaAIDS Research and Human Retroviruses, 1999
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudineClinical Therapeutics, 1996
- Clinical Pharmacokinetics and Metabolism of ChloroquineClinical Pharmacokinetics, 1996
- Comparison of different In Vitro tests for evaluating immune reactivityCell Biochemistry and Function, 1996
- Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1Clinical Therapeutics, 1995
- Inhibition of Human Immunodeficiency Virus Infectivity by ChloroquineAIDS Research and Human Retroviruses, 1990